NLS Pharmaceutics AG (NLSP)
NASDAQ: NLSP · Real-Time Price · USD
2.790
+0.250 (9.84%)
At close: Jun 27, 2025, 4:00 PM
2.850
+0.060 (2.15%)
After-hours: Jun 27, 2025, 7:59 PM EDT
NLS Pharmaceutics AG Employees
As of December 31, 2021, NLS Pharmaceutics AG had 7 total employees, including 6 full-time and 1 part-time employees.
Employees
7
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$579,570
Market Cap
8.82M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2021 | 7 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
NLSP News
- 12 days ago - NLS Pharmaceutics CEO Issues Letter to Shareholders - PRNewsWire
- 5 weeks ago - NLS Pharmaceutics to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual Meeting - PRNewsWire
- 2 months ago - NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models - PRNewsWire
- 3 months ago - NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement - Accesswire
- 4 months ago - NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform - PRNewsWire
- 4 months ago - Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment - PRNewsWire
- 4 months ago - NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies - PRNewsWire
- 5 months ago - Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics - PRNewsWire